Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.42 |
| ▸ | PRKACG | P22612 | 3/20 | 0.42 |
| ▸ | PRKACB | P22694 | 3/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205739 | 0.84 | DYRK1A (0.47) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL28904600 | 0.83 | DYRK1A (0.68) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205501 | 0.82 | DYRK1A (0.55) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205704 | 0.82 | DYRK1A (0.45) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205705 | 0.82 | DYRK1A (0.55) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205505 | 0.82 | DYRK1A (0.76) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205541 | 0.81 | DYRK1A (0.54) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205518 | 0.80 | MAPK14 (0.46) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205693 | 0.80 | DYRK1A (0.53) | DYRK1ACDK5CDK5R1CCNT1CCNA2 | |
| SCHEMBL16205694 | 0.80 | DYRK1A (0.67) | DYRK1ACDK5CDK5R1CCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-17 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | NFKBIA, IKBKG, MAP3K14 | DYRK1A 1007/4885CDK5 841/4885CDK5R1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.